Is laparoscopy for colorectal carcinoma effective and economical even under everyday conditions? A cost-effectiveness analysis in routine Swedish care

被引：0
|
作者：
Voelkel, Vinzenz [1 ]
Fuerst, Alois [1 ]
机构：
[1] Caritas Krankenhaus St Josef, Klin Allgemein, Viszeral, Thoraxchirurg,Adipositasmed, Landshuter Str 65, Regensburg, Germany
来源：
COLOPROCTOLOGY | 2021年 / 43卷 / 02期
关键词：
OPEN SURGERY;
D O I：
10.1007/s00053-021-00527-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：134 / 136
页数：3
相关论文
共 50 条
  • [41] A Cost-effectiveness Analysis of Adding Cetuximab to the First-line Treatment of Metastatic Colorectal Carcinoma in Iran; Considering Genetic Screening for Precision Medicine
    Nazila Yousefi
    Alireza Salimi
    Ghader Mohammadnezhad
    Saeed Taheri
    Farzad Peiravian
    [J]. Journal of Gastrointestinal Cancer, 2023, 54 : 1212 - 1219
  • [42] Monoclonal antibody 17-1A (MAB) adjuvant therapy of resected Dukes' C colorectal carcinoma (CRC): A cost-effectiveness analysis in Germany
    Schadlich, PK
    Lutzelberger, U
    Brecht, JG
    Volmer, T
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 42 - 42
  • [43] A Cost-effectiveness Analysis of Adding Cetuximab to the First-line Treatment of Metastatic Colorectal Carcinoma in Iran; Considering Genetic Screening for Precision Medicine
    Yousefi, Nazila
    Salimi, Alireza
    Mohammadnezhad, Ghader
    Taheri, Saeed
    Peiravian, Farzad
    [J]. JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (04) : 1212 - 1219
  • [44] Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis
    Sajesh K. Veettil
    Siang Tong Kew
    Kean Ghee Lim
    Pochamana Phisalprapa
    Suresh Kumar
    Yeong Yeh Lee
    Nathorn Chaiyakunapruk
    [J]. BMC Gastroenterology, 21
  • [45] Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis
    Veettil, Sajesh K.
    Kew, Siang Tong
    Lim, Kean Ghee
    Phisalprapa, Pochamana
    Kumar, Suresh
    Lee, Yeong Yeh
    Chaiyakunapruk, Nathorn
    [J]. BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [46] Cost-Effectiveness of Routine Monitoring of Long-Term Conditions in Primary Care: Informing Decision Modelling with a Systematic Review in Hypertension, Type 2 Diabetes and Chronic Kidney Disease
    Mohiuddin, Syed G.
    Ward, Mary E.
    Hollingworth, William
    Watson, Jessica C.
    Whiting, Penny F.
    Thom, Howard H. Z.
    [J]. PHARMACOECONOMICS-OPEN, 2024, 8 (03) : 359 - 371
  • [47] Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis
    Westwood, Marie
    Ramos, Isaac Corro
    Lang, Shona
    Luyendijk, Marianne
    Zaim, Remziye
    Stirk, Lisa
    Al, Maiwenn
    Armstrong, Nigel
    Kleijnen, Jos
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (33) : 1 - +
  • [48] COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
    Teich, V
    Fernandes, R. A.
    Schiola, A.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A42 - A42
  • [49] Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System
    Wenwang Lang
    Lian Deng
    Bei Huang
    Dongmei Zhong
    Gaofeng Zhang
    Meijun Lu
    Ming Ouyang
    [J]. Clinical Drug Investigation, 2024, 44 : 149 - 162
  • [50] Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System
    Lang, Wenwang
    Deng, Lian
    Huang, Bei
    Zhong, Dongmei
    Zhang, Gaofeng
    Lu, Meijun
    Ouyang, Ming
    [J]. CLINICAL DRUG INVESTIGATION, 2024, 44 (03) : 149 - 162
12345